Effects of aleglitazar on blood sugar and fat levels in monkeys
Author Information
Author(s): Barbara C Hansen, Xenia Tigno, Agnes Bénardeau, Markus Meyer, Elena Sebokova, Jacques Mizrahi
Primary Institution: University of South Florida
Hypothesis
Does aleglitazar improve glycemic and lipid parameters in a primate model of metabolic syndrome?
Conclusion
Aleglitazar has beneficial effects on both lipid and glucose parameters and may help reduce cardiovascular risk factors in patients with type 2 diabetes.
Supporting Evidence
- Aleglitazar reduced triglyceride levels by an average of 89%.
- It increased HDL cholesterol levels by 125%.
- Aleglitazar improved insulin sensitivity by 60%.
- Mean body weight decreased by 5.9% with aleglitazar treatment.
Takeaway
Aleglitazar is a medicine that helps lower bad fats and blood sugar levels in monkeys, which might help people with diabetes.
Methodology
The study involved a 135-day efficacy assessment in six rhesus monkeys, measuring blood parameters before, during, and after treatment with aleglitazar.
Limitations
The study was conducted on monkeys, and the results may not directly translate to humans.
Participant Demographics
Six adult male rhesus monkeys with metabolic syndrome.
Statistical Information
P-Value
P = 0.0035
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website